Optical coherence tomography reveals retinal structural abnormalities in α-synucleinopathies: insights from the Padua-CESNE cohort.

Publication date: Apr 15, 2025

The complexity of α-synucleinopathies, namely Parkinson’s disease (PD) and multiple system atrophy (MSA), calls for the adoption a multimodal approach integrating biological, morphological, and functional data. Phosphorylated α-synuclein (α-syn) detection in bodily fluids and tissues such as the skin helps provide biological characterization of the disease, but specific and accessible biomarkers are not available yet. The aim of this study was to define the role of Optical Coherence Tomography (OCT, a minimally invasive retinal imaging technique) patterns as possible biomarkers in the early stages of α-synucleinopathies, also supporting the differential diagnosis. Thirty-five (23 PD, 12 MSA), clinically, biologically and genetically characterized patients included in the PADUA-CESNE (Centro Studi per la Neurodegenerazione) cohort underwent OCT. A significant atrophy in the inferior, superior and temporal regions of the Retinal Nerve Fiber Layer (RNFL) and in the inner nuclear layer (INL) were observed in PD compared to controls, differently from MSA. Hyperreflective foci (HRF) counts were elevated across all retinal layers in all patients with PD exhibiting significantly higher numbers, suggesting microglial activation and greater retinal damage. Further research regarding OCT patterns in PD and MSA may consolidate the role of specific features, such as INL abnormalities and different HRF counts, in supporting the diagnosis and differential diagnosis in α-synucleinopathies. In light of the availability of potentially disease-modifying therapies, studies should focus on newly diagnosed patients, also undergoing thorough clinical, biological and genetic characterization.

Open Access PDF

Concepts Keywords
Biomarkers Biomarkers
Invasive Multiple system atrophy
Nuclear Optical coherence tomography
Parkinson Parkinson’s disease
Vienna α-synuclein

Semantics

Type Source Name
disease MESH abnormalities
disease MESH synucleinopathies
disease MESH Parkinson’s disease
disease MESH multiple system atrophy
disease MESH atrophy
drug DRUGBANK Gonadorelin
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH pathological processes
disease MESH Multiple Sclerosis
drug DRUGBANK Dopamine
drug DRUGBANK Esomeprazole
disease MESH Movement Disorder
disease MESH parkinsonism
disease MESH hyperopia
disease MESH astigmatism
disease MESH retinal degeneration
disease MESH glaucoma
disease MESH cataract
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH neurological disorders
disease MESH dysautonomia
drug DRUGBANK Lidocaine
drug DRUGBANK Phosphate ion
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Formic Acid
drug DRUGBANK Gelatin
drug DRUGBANK Glycine
drug DRUGBANK Tricyclazole
drug DRUGBANK Trestolone
disease MESH Diabetic Retinopathy
disease MESH hypertrophy
drug DRUGBANK Coenzyme M
disease MESH visual hallucinations
disease MESH cognitive impairment
disease MESH pathogenesis
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
pathway REACTOME Reproduction
disease MESH syndromes
drug DRUGBANK Tromethamine
disease MESH Alzheimer’s disease
drug DRUGBANK Guanosine
disease MESH orthostatic hypotension
disease MESH gliosis
disease MESH palsy
disease MESH neuroinflammation
pathway KEGG Parkinson disease
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH sclerosis
disease MESH inflammation
disease MESH macular edema
drug DRUGBANK Tretamine
disease MESH aura
drug DRUGBANK Troleandomycin

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *